Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 2.5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection - excipient ingredients: sodium; chloride; octanoate - management of hypovolaemia/shock - albumex 4 may be used to help maintain plasma volume. note that other fluids may be needed in the course of treatment. 2.cardiopulmanary bypass- albumex 4 may be used for priming the pump for cardiopulmanary by pass surgery. it may also be used in the treatment of hypovolaemia following cardiopulmonary by pass surgery. 3.albumex 4 may be used in plasma exchange.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 25 g - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium acetyltryptophanate; water for injections; sodium octanoate - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 12.5 g - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium acetyltryptophanate; sodium octanoate; water for injections - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

Philippines - anglais - FDA (Food And Drug Administration)

zuellig pharma corporation; distributor: zuellig pharma corporation - human albumin - solution for intravenous infusion - 200 g/l (20% w/v)

Philippines - anglais - FDA (Food And Drug Administration)

zuellig pharma corporation; distributor: zuellig pharma corporation - human albumin - solution for intravenous infusion - 200 g/l (20% w/v)

États-Unis - anglais - NLM (National Library of Medicine)

csl behring llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 25 g in 100 ml - albumin is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. if there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. albumin or albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate electrolyte balance. albumin is indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. although diuresis may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained. albuminar® -25 may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

Malte - anglais - Malta Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - anti, d immunoglobulin, human - solution for injection in a pre-filled syringe - anti-d immunoglobulin, human 150 µg/ml - immune sera and immunoglobulins